Skip to content

Prospective, multicenter, single-arm target-value designed clinical trial to evaluate the safety and efficacy of using sinusoidal straight artificial blood vessels for aortic root replacement

Prospective, multicenter, single-arm target-value designed clinical trial to evaluate the safety and efficacy of using sinusoidal straight artificial blood vessels for aortic root replacement

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600119372
Enrollment
Unknown
Registered
2026-02-26
Start date
2026-03-05
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic root replacement

Interventions

Experimental Group:Aortic root replacement

Sponsors

The First Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (1) Aged 18 to 75 years, with no gender restrictions; (2) Patients requiring aortic root replacement; (3) Able to understand the purpose of the trial, willing to participate voluntarily, sign the informed consent form, and accept vascular implantation and clinical follow-up.

Exclusion criteria

Exclusion criteria: Exclusion criteria (1) Subjects who underwent open surgery on the cardiovascular or cerebrovascular system within 3 months prior to screening; (2) Subjects planning to undergo coronary artery bypass grafting or establish hemodialysis access; (3) Subjects with active systemic infection; (4) Subjects with sepsis, active bleeding, refusal to receive blood transfusion, or coagulation dysfunction [Coagulation dysfunction is defined as: 1) Platelet count (PLT) 2.5 times the upper limit of normal]; (5) Subjects known to be allergic to polyester, bovine-derived products, or heparin; (6) Subjects unable to tolerate general anesthesia and cardiopulmonary bypass; (7) Subjects with an expected life expectancy < 6 months (excluding diseases caused by aortic dissection); (8) Subjects currently participating or planning to participate in other clinical studies involving drugs or devices during the trial period; (9) Subjects in pregnancy or lactation, or planning to become pregnant during the study period; (10) Other situations deemed unsuitable for participation in this trial by the investigator.

Design outcomes

Primary

MeasureTime frame
Survival rate [12 months after surgery];

Secondary

MeasureTime frame
Patency rate of artificial blood vessels (from post-operation to discharge, and at 6 months);Structural integrity rate of artificial blood vessels (from postoperative to discharge, and at 6 months);Device success rate (immediately after surgery);Intraoperative blood loss;Intraoperative blood transfusion volume;Length of hospital stay;ICU time;Extracorporeal circulation time;Changes in hemodynamic indicators;

Countries

China

Contacts

Public ContactYang Yan

The First Affiliated Hospital of Xi'an Jiaotong University

yyang376@126.com+86 189 9123 2621

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026